HOME >> MEDICINE >> NEWS
Clarifying controversy in multiple sclerosis

Multiple sclerosis (MS) is a crippling autoimmune disease of the central nervous system (CNS) in which the protective nerve cell coating called myelin is damaged. Although uncontrolled CNS inflammation by immune cells called microglia (MG) and production of the protein TNF-alpha are considered important causes of demyelination and loss of nerve (neuron) function in MS, there is evidence to suggest that a controlled inflammatory response may actually restore damaged myelin and nerve function. Now, in a study appearing online on March 23 in advance of print publication in the April issue of the Journal of Clinical Investigation, researcher Michal Schwartz and colleagues at the Weizmann Institute of Science in Israel help clarify the controversy by reporting that it is the mechanism by which the MGs are activated that determines whether they are destructive or protective. Using both mouse and rat animal models of MS, the authors show that production by immune cells known as helper T cells of small amounts of a proinflammatory protein called IFN-gamma or production of an anti-inflammatory protein IL-4 could stimulate MGs to support nerve cell survival. In contrast, the researchers show that MGs fail to protect neurons when they are exposed to high doses of IFN-gamma, because high levels of IFN-gamma stimulate the MGs to produce TNF-alpha. The results demonstrate that the helper T cells can have direct control over MG action, stimulating them to either support or destroy nerve cell function through production of IL-4, and suggest that stimulation of MGs with IL-4 may help in MS clinical recovery.


'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
23-Mar-2006


Page: 1

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. IOM report should end nevirapine controversy, HIVMA says
3. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
4. University hospitals wins multiple national IT awards for electronic patient data bank
5. Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
6. Glucosamine-like supplement inhibits multiple sclerosis, type 1 diabetes
7. Testosterone may help men with multiple sclerosis
8. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
9. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
10. New GreeneChip identifies multiple pathogens rapidly and accurately
11. GreeneChip -- New diagnostic tool that rapidly and accurately identifies multiple pathogens

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clarifying controversy multiple sclerosis

(Date:9/4/2015)... ... September 04, 2015 , ... Having access to a ... led to an increasing amount of unnecessary emergency room visits which affects hospitals’ abilities ... the country’s health bill. Fortunately, a solution to alleviate this problem has recently presented ...
(Date:9/4/2015)... ... 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third ... men’s 400 meters final, with an impressive 44.89 seconds at the 2015 North American, ... Rica in August 2015. The 44.64 time is a new NACAC Championship record. ...
(Date:9/4/2015)... DC (PRWEB) , ... September 04, 2015 , ... ... they all pale in comparison to settlements under the Stark physician self-referral law. ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will detail ...
(Date:9/4/2015)... NC (PRWEB) , ... September 04, 2015 , ... ... filtration products, has a Labor Day offer that cannot be passed up. ... stock up on necessary air and water filtration product replacements. Take advantage of ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Friday night, ... IL hosting Generation Rescue’s A Night of Hope event supporting families affected by autism, ... and Rowena and Joe Salas, joined together at the Oscar Swan Inn to support ...
Breaking Medicine News(10 mins):Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 About ... in dryness of eyes due to deficient tear production ... This syndrome is of two types: aqueous tear deficient ... deficient dry eye, lacrimal glands do not produce enough ... eye. Meibomian glands secrete lipids to slow tear evaporation ...
(Date:9/3/2015)... Sept. 3, 2015  WellCare Health Plans, Inc. (NYSE: ... , senior vice president and chief financial officer, is ... Healthcare Conference on Wednesday, September 9, 2015, at 9:25 ... webcast live. In addition, a replay of the webcast ... broadcast. Both the live broadcast and the replay will ...
(Date:9/3/2015)... and ALISO VIEJO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical ... medical device company focused on developing ocular implants ... today announced that they have entered into an ... an all-cash transaction.  Under the terms of the ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
Cached News: